Staging of renal cell carcinoma: Past, present, and future

被引:5
|
作者
Nguyen, Carvell T. [1 ]
Campbell, Steven C. [1 ]
机构
[1] Cleveland Clin Fdn, Sect Urol Oncol, Glickman Urol Inst, Cleveland, OH 44195 USA
关键词
adrenal involvement; prognostic factors; TNM stage; venous tumor thrombus;
D O I
10.3816/CGC.2006.n.036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor stage, which describes the anatomic extent of disease, is a powerful determinant of prognosis and survival for patients with renal cell carcinoma (RCC). Stratification of patients based on prognostic outcomes derived from staging systems facilitates therapeutic decision-making, disease surveillance, and clinical research. Staging for RCC has evolved from the Robson classification into the TNM system, developed by the International Union Against Cancer and the American Joint Committee on Cancer. The most recent revisions of the TNM system for RCC introduced in 1997 and 2002 further subdivided organ-confined tumors, reclassified tumors with venous involvement, and clarified the staging of tumors that invade the perisinus fat. Most studies suggest that these revisions have substantially improved prognostication for RCC. Nevertheless, additional modifications have been proposed that would alter the subclassification of organ-confined disease, integrate various levels of venous involvement with other aspects of local tumor aggressiveness, and upgrade the classification of adrenal involvement. The data in support of each of these proposals will be discussed, and the current limitations of clinical and radiographic staging for RCC will be reviewed. Finally, a glimpse into the future of staging of RCC will be offered with a discussion of integrated staging and prognostic systems.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 50 条
  • [1] Staging of nasopharyngeal carcinoma - The past, the present and the future
    Ng, Wai Tong
    Yuen, Kam Tong
    Au, Kwok Hung
    Chan, Oscar S. H.
    Lee, Anne W. M.
    ORAL ONCOLOGY, 2014, 50 (06) : 549 - 554
  • [2] The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma
    Chang, Alexander J.
    Zhao, Lei
    Zhu, Ziwen
    Boulanger, Kyle
    Xiao, Huaping
    Wakefield, Mark R.
    Bai, Qian
    Fang, Yujiang
    ANTICANCER RESEARCH, 2019, 39 (06) : 2683 - 2687
  • [3] Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
    Pal, Sumanta K.
    Haas, Naomi B.
    ONCOLOGIST, 2014, 19 (08): : 851 - 859
  • [4] Cellular therapy of renal cell carcinoma past, present, future
    Figlin, R
    Mulders, P
    Gitlitz, B
    Belldegrun, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 31 - 31
  • [5] Treatment options in renal cell carcinoma: past, present and future
    Oudard, S.
    George, D.
    Medioni, J.
    Motzer, R.
    ANNALS OF ONCOLOGY, 2007, 18 : 25 - 31
  • [6] Treatment strategies for clear cell renal cell carcinoma: Past, present and future
    Yang, Junwei
    Wang, Kuansong
    Yang, Zhichun
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Treatment approaches in renal cell carcinoma: Past, present, and future perspectives
    Albers, Peter
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (02) : 36 - 45
  • [8] Adjuvant Therapy in Renal Cell Carcinoma-Past, Present, and Future
    Janowitz, Tobias
    Welsh, Sarah J.
    Zaki, Kamarul
    Mulders, Peter
    Eisen, Tim
    SEMINARS IN ONCOLOGY, 2013, 40 (04) : 482 - 491
  • [9] Merkel Cell Carcinoma: The Past, the Present, and the Future
    Erovic, Inamaria
    Erovic, Boban M.
    JOURNAL OF SKIN CANCER, 2013, 2013
  • [10] PET/CT for Staging; Past, Present, and Future
    El-Galaly, Tarec Christoffer
    Gormsen, Lars Christian
    Hutchings, Martin
    SEMINARS IN NUCLEAR MEDICINE, 2018, 48 (01) : 4 - 16